|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
Statistics, 2017. CA Cancer J Clin. 67:7–30. 2017.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Suh DH, Kim M, Kim K, Kim HJ, Lee KH and
Kim JW: Major clinical research advances in gynecologic cancer in
2016: 10-year special edition. J Gynecol Oncol.
28(e45)2017.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Miller KD, Siegel RL, Lin CC, Mariotto AB,
Kramer JL, Rowland JH, Stein KD, Alteri R and Jemal A: Cancer
treatment and survivorship statistics, 2016. CA Cancer J Clin.
66:271–289. 2016.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Chornokur G, Amankwah EK, Schildkraut JM
and Phelan CM: Global ovarian cancer health disparities. Gynecol
Oncol. 129:258–264. 2013.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Croce CM: Causes and consequences of
microRNA dysregulation in cancer. Nat Rev Genet. 10:704–714.
2009.PubMed/NCBI View
Article : Google Scholar
|
|
7
|
Zaman MS, Maher DM, Khan S, Jaggi M and
Chauhan SC: Current status and implications of microRNAs in ovarian
cancer diagnosis and therapy. J Ovarian Res. 5(44)2012.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Langhe R: microRNA and ovarian cancer. Adv
Exp Med Biol. 889:119–151. 2015.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Xu N, Yang W, Liu Y, Yan F and Yu Z:
MicroRNA-411 promoted the osteosarcoma progression by suppressing
MTSS1 expression. Environ Sci Pollut Res Int. 25:12064–12071.
2018.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Zhao Z, Qin L and Li S: miR-411
contributes the cell proliferation of lung cancer by targeting
FOXO1. Tumour Biol. 37:5551–5560. 2016.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Nadal E, Zhong J, Lin J, Reddy RM, Ramnath
N, Orringer MB, Chang AC, Beer DG and Chen G: A MicroRNA cluster at
14q32 drives aggressive lung adenocarcinoma. Clin Cancer Res.
20:3107–3117. 2014.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Xia K, Zhang Y, Cao S, Wu Y, Guo W, Yuan W
and Zhang S: miR-411 regulated ITCH expression and promoted cell
proliferation in human hepatocellular carcinoma cells. Biomed
Pharmacother. 70:158–163. 2015.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Zeljic K, Jovanovic I, Jovanovic J, Magic
Z, Stankovic A and Supic G: MicroRNA meta-signature of oral cancer:
Evidence from a meta-analysis. Ups J Med Sci. 123:43–49.
2018.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Zhang X, Zhang M, Cheng J, Lv Z, Wang F
and Cai Z: MiR-411 functions as a tumor suppressor in renal cell
cancer. Int J Biol Markers. 32:e454–e460. 2017.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Shan D, Shang Y and Hu T: MicroRNA-411
inhibits cervical cancer progression by directly targeting STAT3.
Oncol Res. 27:349–358. 2018.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Guo L, Yuan J, Xie N, Wu H, Chen W, Song S
and Wang X: miRNA-411 acts as a potential tumor suppressor miRNA
via the downregulation of specificity protein 1 in breast cancer.
Mol Med Rep. 14:2975–2982. 2016.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Zhang Y, Xu G, Liu G, Ye Y, Zhang C, Fan
C, Wang H, Cai H, Xiao R, Huang Z and Luo Q: miR-411-5p inhibits
proliferation and metastasis of breast cancer cell via targeting
GRB2. Biochem Biophys Res Commun. 476:607–613. 2016.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Zhao J, Xu J and Zhang R: MicroRNA-411
inhibits malignant biological behaviours of colorectal cancer cells
by directly targeting PIK3R3. Oncol Rep. 39:633–642.
2018.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Deguchi S, Katsushima K, Hatanaka A,
Shinjo K, Ohka F, Wakabayashi T, Zong H, Natsume A and Kondo Y:
Oncogenic effects of evolutionarily conserved noncoding RNA
ECONEXIN on gliomagenesis. Oncogene. 36:4629–4640. 2017.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Sun M, Huang F, Yu D, Zhang Y, Xu H, Zhang
L, Li L, Dong L, Guo L and Wang S: Autoregulatory loop between
TGF-β1/miR-411-5p/SPRY4 and MAPK pathway in rhabdomyosarcoma
modulates proliferation and differentiation. Cell Death Dis.
6(e1859)2015.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Yamamoto K, Seike M, Takeuchi S, Soeno C,
Miyanaga A, Noro R, Minegishi Y, Kubota K and Gemma A: MiR-379/411
cluster regulates IL-18 and contributes to drug resistance in
malignant pleural mesothelioma. Oncol Rep. 32:2365–2372.
2014.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Kozomara A, Birgaoanu M and
Griffiths-Jones S: miRBase: From microRNA sequences to function.
Nucleic Acids Res. 47:D155–D162. 2019.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Yang JH, Li JH, Shao P, Zhou H, Chen YQ
and Qu LH: starBase: A database for exploring microRNA-mRNA
interaction maps from Argonaute CLIP-Seq and Degradome-Seq data.
Nucleic Acids Res. 39:D202–D209. 2011.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Kim YW, Kim EY, Jeon D, Liu JL, Kim HS,
Choi JW and Ahn WS: Differential microRNA expression signatures and
cell type-specific association with Taxol resistance in ovarian
cancer cells. Drug Des Devel Ther. 8:293–314. 2014.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Wang SY, Li Y, Jiang YS and Li RZ:
Investigation of serum miR-411 as a diagnosis and prognosis
biomarker for non-small cell lung cancer. Eur Rev Med Pharmacol
Sci. 21:4092–4097. 2017.PubMed/NCBI
|
|
27
|
Zhang C, Wang H, Liu X, Hu Y, Ding L,
Zhang X, Sun Q and Li Y: Oncogenic microRNA-411 promotes lung
carcinogenesis by directly targeting suppressor genes SPRY4 and
TXNIP. Oncogene. 38:1892–1904. 2019.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Ai P, Shen B, Pan H, Chen K, Zheng J and
Liu F: MiR-411 suppressed vein wall fibrosis by downregulating
MMP-2 via targeting HIF-1α. J Thromb Thrombolysis. 45:264–273.
2018.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Wang G, Zhang Y, Zhao X, Meng C, Ma L and
Kong Y: MicroRNA-411 inhibited matrix metalloproteinase 13
expression in human chondrocytes. Am J Transl Res. 7:2000–2006.
2015.PubMed/NCBI
|
|
30
|
Chen H, Mohan P, Jiang J, Nemirovsky O, He
D, Fleisch MC, Niederacher D, Pilarski LM, Lim CJ and Maxwell CA:
Spatial regulation of Aurora A activity during mitotic spindle
assembly requires RHAMM to correctly localize TPX2. Cell Cycle.
13:2248–2261. 2014.PubMed/NCBI View
Article : Google Scholar
|
|
31
|
Wang D, Narula N, Azzopardi S, Smith RS,
Nasar A, Altorki NK, Mittal V, Somwar R, Stiles BM and Du YN:
Expression of the receptor for hyaluronic acid mediated motility
(RHAMM) is associated with poor prognosis and metastasis in
non-small cell lung carcinoma. Oncotarget. 7:39957–39969.
2016.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Stevens LE, Cheung WKC, Adua SJ,
Arnal-Estapé A, Zhao M, Liu Z, Brewer K, Herbst RS and Nguyen DX:
Extracellular matrix receptor expression in subtypes of lung
adenocarcinoma potentiates outgrowth of micrometastases. Cancer
Res. 77:1905–1917. 2017.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Turley EA, Noble PW and Bourguignon LY:
Signaling properties of hyaluronan receptors. J Biol Chem.
277:4589–4592. 2002.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Adamia S, Maxwell CA and Pilarski LM:
Hyaluronan and hyaluronan synthases: Potential therapeutic targets
in cancer. Curr Drug Targets Cardiovasc Haematol Disord. 5:3–14.
2005.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Roskoski R Jr: ERK1/2 MAP kinases:
Structure, function, and regulation. Pharmacol Res. 66:105–143.
2012.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Holmström TH, Tran SE, Johnson VL, Ahn NG,
Chow SC and Eriksson JE: Inhibition of mitogen-activated kinase
signaling sensitizes HeLa cells to Fas receptor-mediated apoptosis.
Mol Cell Biol. 19:5991–6002. 1999.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Huang C, Jacobson K and Schaller MD: MAP
kinases and cell migration. J Cell Sci. 117:4619–4628.
2004.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Mansour SJ, Resing KA, Candi JM, Hermann
AS, Gloor JW, Herskind KR, Wartmann M, Davis RJ and Ahn NG:
Mitogen-activated protein (MAP) kinase phosphorylation of MAP
kinase kinase: Determination of phosphorylation sites by mass
spectrometry and site-directed mutagenesis. J Biochem. 116:304–314.
1994.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Steinmetz R, Wagoner HA, Zeng P, Hammond
JR, Hannon TS, Meyers JL and Pescovitz OH: Mechanisms regulating
the constitutive activation of the extracellular signal-regulated
kinase (ERK) signaling pathway in ovarian cancer and the effect of
ribonucleic acid interference for ERK1/2 on cancer cell
proliferation. Mol Endocrinol. 18:2570–2582. 2004.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Amsterdam A, Shezen E, Raanan C, Schreiber
L, Prus D, Slilat Y, Ben-Arie A and Seger R: Nuclear localization
of phosphorylated ERK1 and ERK2 as markers for the progression of
ovarian cancer. Int J Oncol. 39:649–656. 2011.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Hatano H, Shigeishi H, Kudo Y, Higashikawa
K, Tobiume K, Takata T and Kamata N: Overexpression of receptor for
hyaluronan-mediated motility (RHAMM) in MC3T3-E1 cells induces
proliferation and differentiation through phosphorylation of
ERK1/2. J Bone Miner Metab. 30:293–303. 2012.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Hamilton SR, Fard SF, Paiwand FF, Tolg C,
Veiseh M, Wang C, McCarthy JB, Bissell MJ, Koropatnick J and Turley
EA: The hyaluronan receptors CD44 and Rhamm (CD168) form complexes
with ERK1,2 that sustain high basal motility in breast cancer
cells. J Biol Chem. 282:16667–16680. 2007.PubMed/NCBI View Article : Google Scholar
|
